Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

b. braun medical inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime for injection usp and dextrose injection usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes, and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin-structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes, escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and kle

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

hospira nz ltd - cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime - powder for injection - 1500 mg - active: cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

hospira nz ltd - cefuroxime sodium 263mg equivalent to 250 mg cefuroxime - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to 250 mg cefuroxime

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

hospira nz ltd - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime

Իսրայել - անգլերեն - Ministry of Health

novartis israel ltd., israel - cefuroxime as sodium - powder for solution or suspension for injection or infusion - cefuroxime as sodium 750 mg/vial - cefuroxime - cefuroxime - therapeutic indications zinacef is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth)• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section) • nose infections for example, sinusitis • septic arthritis

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

hospira, inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime for injection and other antibacterial drugs, cefuroxime for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. cefuroxime for injection has been used successfully in these mixed infections in which several organisms have been isolated. in certai

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

direct rx - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets usp and other antibacterial drugs, cefuroxime axetil tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. note: cefuroxime axetil tablets usp and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets usp: cefuroxime axetil tablets usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   - pharyngitis/tonsillitis cause

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - cefuroxime sodium 1.578 g equivalent to 1.5 g cefuroxime;  ;   - powder for injection - 1.5 g - active: cefuroxime sodium 1.578 g equivalent to 1.5 g cefuroxime     - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include - respiratory tract infections for example, acute exacerbation of chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septic ar

Կանադա - անգլերեն - Health Canada

fresenius kabi canada ltd - cefuroxime (cefuroxime sodium) - powder for solution - 750mg - cefuroxime (cefuroxime sodium) 750mg - second generation cephalosporins

Կանադա - անգլերեն - Health Canada

fresenius kabi canada ltd - cefuroxime (cefuroxime sodium) - powder for solution - 1.5g - cefuroxime (cefuroxime sodium) 1.5g - second generation cephalosporins